Outcomes-based contracts could increase the willingness of payers to provide beneficiaries with high-cost genetic drug therapies.
The alternative payment model, according to a HealthPayerIntelligence.Com report, would ease the financial risk taken by payers.
CVS Specialty Chief Medical Officer Dr. Surya Singh says the contracts would be a step in the right direction.
“A thoughtful approach to selecting or constructing the right value-based model for different drug categories will help to catalyze the movement (towards value-based care) and ensure that the right drug reaches the right patient at the right time,” Singh told HealthPayerIntelligence.Com.
To read more about how outcomes-based agreements could impact payer decisions, click here.